Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1Breast 1

Conditions

Prostatic Neoplasms 5Carcinoma, Non-Small-Cell Lung 3Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Radiation Injuries 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Meningioma 1Glioblastoma 1Frailty 1Esophageal Neoplasms 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Anatomic Stage IV Breast Cancer AJCC v8 1Advanced Lung Neuroendocrine Tumor 1

Interventions

Magnetic Resonance Spectroscopy 3Specimen Handling 2Biopsy 2radium Ra 223 dichloride 1pembrolizumab 1binimetinib 1abemaciclib 1X-Rays 1Vorinostat 1Taxes 1Tamoxifen 1Steroids 1Photons 1Paclitaxel 1Letrozole 1Imatinib Mesylate 1Hormones 1Fulvestrant 1Cyclin-Dependent Kinase Inhibitor p18 1Cyclin-Dependent Kinase Inhibitor p16 1Capecitabine 116-fluoroestradiol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Anatomic Stage IV Breast Cancer AJCC v8 × Photons × Clear all
NCT04090398 2026-05-13

Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones

National Cancer Institute (NCI)

Phase 2 Active not recruiting
70 enrolled
BreastOther neoplasm

Anatomic Stage IV Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡